^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) + Partruvix (pamiparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Excerpt:
Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD
Trial ID:
Source:
Title:
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial
Published date:
07/20/2023
Excerpt:
Patients with EOC with BRCAmut and/or HRD had an ORR of 30.4% (seven of 23 patients), with a CR rate of 8.7%...In conclusion, pamiparib in combination with tislelizumab showed evidence of antitumour activity in patients with advanced solid tumours, particularly those with BRCAmut and/or HRD tumours, with a manageable safety profile in keeping with the class of agents. This study supports further investigation of this combination strategy, particularly in patients with TNBC with BRCAmut and/or HRD.
DOI:
10.1038/s41416-023-02349-0
Trial ID:
